Meeting Minutes: Drug Formulary Committee - DRAFT

Date & Time: August 26, 2020; 5:30-9:00 PM
Minutes prepared by: Justin Johnson and Dave Hoang
Location: Virtual Meeting via Zoom

Attendance

- Members in attendance: Stuart Williams, J.D.; Margaret Artz, RPh., PhD.; Mary Mescher Benbenek, APRN, PhD.; Monica Brands, RPh.; Kathryn Lombardo, MD.; James Phillips, MD.; Ramona Powell, PharmD.; Kelly Ruby, PharmD.; Michael Sprehe, MD.;
- Members absent: Al Heaton, PharmD.; Kyle Lehenbauer, MD.
- DHS staff present: Dave Hoang, PharmD., MBA; Chad Hope, PharmD.; Nathan Chomilo, MD.;
- Others in attendance: Ariane Casey, PharmD.; Justin Johnson, PharmD.

Report of the Chair

- Stuart Williams presided over the meeting.

Approval of Minutes

- Minutes from the March 2020 and June 2020 meetings were reviewed and accepted with the following change:
  - Change the second bullet on the June 2020 minutes in the “New Specialty Drugs for Continued PA” section to “The committee discussed Caplyta and recommended to the department by a unanimous vote that Caplyta remain on PA with the proposed criteria.”

DHS Housekeeping - None

Old Business – None

New Business

New Specialty Drugs for Continued PA

- The committee discussed Tepezza and recommended to the department by a unanimous vote that Tepezza remain on PA with the proposed criteria, with the following change:
  - Change the 10th bullet of the initial approval criteria to “Patient has active phase TED that is non-sight threatening but has a significant impact on daily living (e.g., lid retraction ≥ 2 mm,”
moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal, and/or inconstant or constant diplopia); AND”.

• The committee discussed Ayvakit and recommended to the department by a unanimous vote that Ayvakit remain on PA with the proposed criteria.

• The committee discussed Sarclisa and recommended to the department by a unanimous vote that Sarclisa remain on PA with the proposed criteria, with the following change:
  o Change the 3rd bullet of the renewal criteria to “Patient has NOT experienced any treatment-restricting adverse effects (e.g., severe infusion reactions including anaphylactic reactions, neutropenia, secondary primary malignancies).”

• The committee discussed Valtoco and recommended to the department by a majority vote that Valtoco remain on PA with the proposed criteria. The committee also made a recommendation to review the PA criteria in 6 months after the department engages the manufacturers of products within this PDL category with the goal of having at least 1 preferred nasal product.

• The committee discussed Pemazyre and recommended to the department by a unanimous vote that Pemazyre remain on PA with the proposed criteria.

• The committee discussed Tukysa and recommended to the department by a unanimous vote that Tukysa remain on PA with the proposed criteria, with the following change:
  o Change the 3rd bullet of the renewal criteria to “Absence of unacceptable toxicity from the drug (e.g., hepatotoxicity [severe changes in liver function tests], severe diarrhea).”

• The committee discussed Fensolvi and recommended to the department by a unanimous vote that Fensolvi remain on PA with the proposed criteria.

• The committee discussed Trodelvy and recommended to the department by a unanimous vote that Trodelvy remain on PA with the proposed criteria.

• The committee discussed Durysta and recommended to the department by a unanimous vote that Durysta remain on PA with the proposed criteria.

• The committee discussed Tabrecta and recommended to the department by a unanimous vote that Tabrecta remain on PA with the proposed criteria.

• The committee discussed Retevmo and recommended to the department by a unanimous vote that Retevmo remain on PA with the proposed criteria.

• The committee discussed Xcopri and recommended to the department by a unanimous vote that Xcopri remain on PA with the proposed criteria, with the following change:
  o Change the 3rd bullet of the initial criteria to “Patient does NOT have familial short QT syndrome; AND”
• The committee discussed Vumerity and recommended to the department by a unanimous vote that Vumerity remain on PA with the proposed criteria, with the following change:
  o Change the 7th bullet to “Patient has had inadequate response§ after a 6-month adherent trial of dimethyl fumurate or Tecfidera with unacceptable GI side effects, unless contraindicated”.

• The committee discussed Zeposia and recommended to the department by a unanimous vote that Zeposia remain on PA with the proposed criteria.

• The committee discussed Oriahnn and recommended to the department by a unanimous vote that Oriahnn remain on PA with the proposed criteria, with the following change:
  o Change the 7th bullet of the initial criteria to “Patients of childbearing potential will use effective non-hormonal contraception during treatment with Oriahnn and 1 week after stopping therapy; AND”

Existing Specialty Drugs for Continued PA

• The committee discussed Synagis and recommended to the department by a unanimous vote that Synagis remain on PA with the proposed criteria.

New Drugs for Continued PA

• The committee discussed Nexletol/Nexlizet and recommended to the department by a unanimous vote that Nexletol/Nexlizet remain on PA with the proposed criteria.

• The committee discussed Dayvigo and recommended to the department by a unanimous vote that Dayvigo remain on PA with the proposed criteria with the following change:
  o Change to the 5th bullet of the initial approval criteria to “Patient must have a 1 month trial of the following medications (unless contraindicated):
    ▪ eszopiclone; AND
    ▪ zolpidem; AND
    ▪ zaleplon”
  o Change the 12th bullet of the initial approval criteria to “Prescriber attests that concurrent medications that may contribute to insomnia have been reviewed.”

Uniform Preferred Drug List Prior Authorization Criteria

• The committee discussed the Continuation of Therapy Prior Authorization Criteria and recommended to the department by a unanimous vote that the proposed criteria be adopted.

• The committee discussed the Nonpreferred Drug Prior Authorization Criteria and recommended to the department by a unanimous vote that the proposed criteria be adopted with the following change:
  o Change the Definition to “Free goods/pharmaceutical samples: medication samples, medications obtained from any patient assistance programs or any discount programs, medications obtained through free trial programs, manufacturer vouchers, coupons or debit cards while on Medical Assistance.”
Adjudgment

- The meeting was adjourned at approximately 10:05 PM Central Time.